AMX-3009 Maleate

AMX-3009马来酸

Report date: 2026/04/30 20:00:20
NME

Base Information

Drug NameAMX-3009 Maleate
Drug Alias NameAMX-3009AMX3009马来酸
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitors
TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAnrun Medicine Technology (Suzhou) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAnrun Medicine Technology (Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[4] 
Inactive IndicationsPancreatic NeoplasmsStomach NeoplasmsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A